FilingSEC EDGAR10-K
Neuphoria Therapeutics Announces Proposed Merger with Scancell and Closing Conditions
· SEC accepted
StageProposed Merger
Filing content
The company disclosed closing conditions for its proposed merger with Scancell, including shareholder approval, $75.0 million in financing, and a $10.0 million net cash requirement.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…